Quote:
Originally Posted by johnt
Tupelo3,
Thank you and Girija for looking into this.
The approach is exciting.
I have many questions. Most can wait. But one needs answering quickly. You write:
"Understand, no one else in the world can conduct this research. Northeastern and their corporate partner, Copernicus Therapeutics, own the patent rights to the drug."
Supposing that this approach works, what is your understanding of their pricing strategy?
John
|
John, I'm really not sure about the answer to your question as Barbara's main focus now is just to get into human trials. Honestly, Barbara is a genius when it comes to the biology and chemistry of human brain cells. However, she isn't very knowledgeable, yet, on the drug approval process. So, I would think that pricing a future drug, if approved, is way down her list of priorities. I also think that Copernicus has more say in that regard, and we haven't spoken with them yet, although I do intend too. If I get the chance, I will definitely ask that question.
Gary